Abstracts tagged "registry"

Abstract Number: 676 • 2014 ACR/ARHP Annual Meeting
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register
Emily Sutton¹, Kath D. Watson², David A. Isenberg³, Anisur Rahman⁴, David Jayne⁵, Caroline Gordon⁶, Ben Parker⁷, David P. D'Cruz⁸, Munther A. Khamashta⁹, Pamela Lutalo¹⁰, Peter Lanyon¹¹, Benjamin Rhodes¹², Bridget Griffiths¹³, Edward M. Vital¹⁴, Chee-Seng Yee¹⁵, Christopher Edwards¹⁶, Mohammed Akil¹⁷, Nicola Erb¹⁸, Athiveer Prabu¹⁹, Asad A. Zoma²⁰, Neil McHugh²¹, Hazem Youssef²², Lee-Suan Teh²³, Michael W. Beresford²⁴ and Ian N. Bruce²⁵, ¹University of Manchester, Manchester Academic Health Science Centre, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ³Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research, University College London, London, United Kingdom, ⁵Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁶Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, ⁷Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁸Louise Coote Lupus Unit, Guy's and St Thomas' Hospital, London, United Kingdom, ⁹Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ¹⁰Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ¹¹Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, ¹²Rheumatology, Queen Elizabeth Hospital, Birmingham, United Kingdom, ¹³Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds., United Kingdom, Leeds, United Kingdom, ¹⁵Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom, ¹⁶Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁷Rheumatology Department, Sheffield South Yorkshire, United Kingdom, ¹⁸Rheumatology, Russells Hall Hospital, Dudley, United Kingdom, ¹⁹Department of Rheumatology, Worcester Acute Hospitals NHS Trust, Worcester, United Kingdom, ²⁰Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, ²¹Rheumatology, Royal National Hospital, Bath, United Kingdom, ²²Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom, ²³Department of Rhuematology, Royal Blackburn Hospital, Blackburn, United Kingdom, ²⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ²⁵Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Published efficacy data for rituximab in SLE are complex with positive single-centre case series and negative randomised controlled trials. This may be due to…
Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting
Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry
Leslie R. Harrold¹, George W. Reed^1,2, Chitra Karki³, Robert Magner¹, Ashwini Shewade⁴, Ani John⁴, Joel M. Kremer⁵ and Jeffrey D. Greenberg^3,6, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC., Southborough, MA, ³Corrona, LLC, Southborough, MA, ⁴Genentech, Inc, South San Francisco, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].